PURE Bioscience Announces DuraBan International as Distributor of SDC-Based Disinfectant

PURE Bioscience Announces DuraBan International as Distributor of SDC-Based
Disinfectant
DuraClean(TM) to Launch in Multiple Markets, Including Industrial Contracted
Services

SAN DIEGO, July 31 /PRNewswire-FirstCall/ -- PURE Bioscience
(Nasdaq: PURE) today announced an agreement with DuraBan International Inc for
distribution of PURE's silver dihydrogen citrate (SDC)-based disinfectant
under DuraBan's DuraClean(TM) brand.
(Logo: http://www.newscom.com/cgi-bin/prnh/20060119/LATH060LOGO)
DuraBan International Inc, a Minneapolis based chemical manufacturer
specializing in earth-friendly antimicrobial technologies, intends to sell
DuraClean through its existing distribution channels into multiple markets,
including the building, consumer products, medical, service and industrial
sectors.
Robert Dahl, founder of DuraBan, commented, "DuraBan's foundation has been
built on providing earth-friendly antimicrobial solutions, of which SDC
powered DuraClean is a perfect example. We expect it to provide an
attractive, effective and efficient solution for our customers, as DuraBan
stays true to its heritage of providing safe, effective and efficient
solutions to our customers in the worldwide consumer, industrial and medical
marketplace."
Michael L. Krall, President and CEO of PURE Bioscience, stated, "SDC is a
perfect complement for DuraBan's product line, which features safe and green
antimicrobial barrier technologies. DuraClean will be marketed through
DuraBan's established distribution channels. These channels include a wide
variety of markets, some of which will be significant new entry points for our
SDC-based disinfectant, such as the industrial contracted services area."
DuraBan has registered DuraClean with the US EPA as a sub-registrant of
PURE Bioscience and is currently undergoing registration in all 50 states. In
accordance with the agreement, each bottle of DuraClean features PURE's
"Powered by SDC" logo. The contract also provides for increasing annual
minimum purchases; other specific terms of the contract were not disclosed.
DuraClean disinfectant carries a 30 second kill time on standard indicator
bacteria, a 24 hour residual kill on standard indicator bacteria, a 2 minute
kill time on some resistant strains of bacteria, 10 minute kill time on fungi,
30 second kill time on HIV Type I, and 10 minute kill time on other pathogenic
viruses. These claims distinguish the efficacy of DuraClean from many of the
leading commercial and consumer products currently on the market, while
maintaining lower toxicity ratings. Based on the EPA toxicity ratings from
Category I (high toxicity) down to Category IV, DuraClean is a Category IV
antimicrobial for which precautionary labeling statements are not required.
This compares with Category II warning statements for most leading brands of
disinfectant products.
About DuraBan
DuraBan International Inc, is a Minneapolis, Minn., based chemical
manufacturer and emerging global innovator of built-in, earth-friendly,
antimicrobial product protection. DuraBan engineers safe and durable
antimicrobial solutions for consumer, industrial and medical products around
the world. Its technology can be engineered into a variety of surfaces and
materials including: coatings, polymers, textiles, lumber, plastic and
adhesives. Built-in to products during the manufacturing process, DuraBan
antimicrobial product protection inhibits the growth of microbes, such as
bacteria, mold and mildew that can cause stains, odors and product
deterioration. DuraBan's proprietary and patented antimicrobial technologies
deliver unmatched performance, durability and efficacy through a unique
formulation based on surface-modifying nanotechnology. Once applied, DuraBan
chemically bonds to the product surface, creating a permanent antimicrobial
barrier that destroys microorganisms upon contact. DuraBan's antimicrobial
has never been shown to allow or cause microbial adaptation, resistance,
mutation, diffusion, or migration and easily bonds to almost any surface,
creating unlimited applications for this breakthrough technology. For more
information, please visit http://www.durabanintl.com.
About PURE Bioscience
PURE Bioscience develops and markets technology-based bioscience products
that provide solutions to numerous global health challenges, including Staph
(MRSA). PURE's proprietary high efficacy/low toxicity bioscience technologies,
including its silver dihydrogen citrate-based antimicrobials, represent
innovative advances in diverse markets and lead today's global trend toward
industry and consumer use of "green" products while providing competitive
advantages in efficacy and safety. Patented SDC is an electrolytically
generated source of stabilized ionic silver which formulates well with other
compounds. As a platform technology, SDC is distinguished from competitors in
the marketplace because of its superior efficacy, reduced toxicity and the
inability of bacteria to form a resistance to it. PURE is headquartered in El
Cajon, California (San Diego metropolitan area). Additional information on
PURE is available at http://www.purebio.com.
This press release includes statements that may constitute
"forward-looking" statements, usually containing the words "believe,"
"estimate," "project," "expect" or similar expressions. These statements are
made pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements inherently involve
risks and uncertainties that could cause actual results to differ materially
from the forward-looking statements. Factors that would cause or contribute to
such differences include, but are not limited to, acceptance of the Company's
current and future products and services in the marketplace, the ability of
the Company to develop effective new products and receive regulatory approvals
of such products, competitive factors, dependence upon third-party vendors,
and other risks detailed in the Company's periodic report filings with the
Securities and Exchange Commission. By making these forward-looking
statements, the Company undertakes no obligation to update these statements
for revisions or changes after the date of this release.
PURE Bioscience Investor Contact:
Paul G. Henning, Vice President
Cameron Associates
(212) 554-5462
paul@cameronassoc.com

SOURCE PURE Bioscience

Paul G. Henning, Vice President of Cameron Associates, +1-212-554-5462,
paul@cameronassoc.com, for PURE Bioscience